Stealth BioTherapeutics Corp. ADS
MITO
MITO was delisted on the 15th of November, 2022.
10 hedge funds and large institutions have $947K invested in Stealth BioTherapeutics Corp. ADS in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
100% more funds holding
Funds holding: 5 → 10 (+5)
26% more capital invested
Capital invested by funds: $752K → $947K (+$195K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$748K |
| 2 |
Renaissance Technologies
New York
|
+$284K |
| 3 |
Millennium Management
New York
|
+$80.1K |
| 4 |
PC
PA Capital
Richmond,
Virginia
|
+$49.9K |
| 5 |
Two Sigma Investments
New York
|
+$27.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$14.7K |
| 2 |
Morgan Stanley
New York
|
-$11.1K |
MITO Hedge Fund Activity: Q1 2020 in Review
10 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Stealth BioTherapeutics Corp. ADS (MITO) for Q1 2020, worth a combined $947K — up 26% from $752K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new MITO positions and 1 closed out — a net gain of 5 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Prosight Management, opening a new position worth an estimated $748K. The largest seller was UBS Group, cutting an estimated $14.7K.
- 10 institutional investors held Stealth BioTherapeutics Corp. ADS (MITO) as of Q1 2020, up from 5 in Q4 2019.
- Funds reported $947K of Stealth BioTherapeutics Corp. ADS stock for Q1 2020, up 26% quarter-over-quarter.
- 6 funds opened new Stealth BioTherapeutics Corp. ADS positions in Q1 2020 and 1 closed out, a net change of +5 holders.
- The largest Stealth BioTherapeutics Corp. ADS buyer in Q1 2020 was Prosight Management, an estimated $748K added.
- The largest Stealth BioTherapeutics Corp. ADS seller in Q1 2020 was UBS Group, an estimated $14.7K sold.
Based on aggregated 13F filings for Q1 2020.